Exhibit 1

JOINT FILING AGREEMENT

The undersigned hereby agree that Amendment No. 2 to Schedule 13D, dated November 14, 2023 with respect to the Ordinary Shares and American Depository Shares of Chemomab Therapeutics Ltd. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, Each of the undersigned agrees to be responsible for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein. This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the 15^th day of November 2023.

By:		/s/ Carl L. Gordon
		Name: Carl L. Gordon
By:		/s/ Erez Chimovits
		Name: Erez Chimovits
ORBIMED ISRAEL BIOFUND GP LIMITED PARTNERSHIP
By:	OrbiMed Israel GP Ltd., its General Partner
By:	/s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Director
ORBIMED ISRAEL GP LTD.
By:	/s/ Carl L. Gordon
	Name: Carl L. Gordon
	Title: Director